Istituto Italiano di Tecnologia , via Morego 30 , 16163 Genoa , Italy.
Dipartimento di Chimica e Chimica Industriale , Università di Genova , Via Dodecaneso, 31 , 16146 Genova , Italy.
ACS Appl Mater Interfaces. 2019 Feb 13;11(6):5727-5739. doi: 10.1021/acsami.8b16226. Epub 2019 Feb 1.
The use of magnetic nanoparticles in oncothermia has been investigated for decades, but an effective combination of magnetic nanoparticles and localized chemotherapy under clinical magnetic hyperthermia (MH) conditions calls for novel platforms. In this study, we have engineered magnetic thermoresponsive iron oxide nanocubes (TR-cubes) to merge MH treatment with heat-mediated drug delivery, having in mind the clinical translation of the nanoplatform. We have chosen iron oxide based nanoparticles with a cubic shape because of their outstanding heat performance under MH clinical conditions, which makes them benchmark agents for MH. Accomplishing a surface-initiated polymerization of strongly interactive nanoparticles such as our iron oxide nanocubes, however, remains the main challenge to overcome. Here, we demonstrate that it is possible to accelerate the growth of a polymer shell on each nanocube by simple irradiation of a copper-mediated polymerization with a ultraviolet light (UV) light, which both speeds up the polymerization and prevents nanocube aggregation. Moreover, we demonstrate herein that these TR-cubes can carry chemotherapeutic doxorubicin (DOXO-loaded-TR-cubes) without compromising their thermoresponsiveness both in vitro and in vivo. In vivo efficacy studies showed complete tumor suppression and the highest survival rate for animals that had been treated with DOXO-loaded-TR-cubes, only when they were exposed to MH. The biodistribution of intravenously injected TR-cubes showed signs of renal clearance within 1 week and complete clearance after 5 months. This biomedical platform works under clinical MH conditions and at a low iron dosage, which will enable the translation of dual MH/heat-mediated chemotherapy, thus overcoming the clinical limitation of MH: i.e., being able to monitor tumor progression post-MH-treatment by magnetic resonance imaging (MRI).
几十年来,人们一直在研究将磁性纳米粒子用于肿瘤热疗,但在临床磁热疗 (MH) 条件下,将磁性纳米粒子与局部化疗有效结合需要新型平台。在这项研究中,我们设计了磁性热响应氧化铁纳米立方(TR-立方),将 MH 治疗与热介导药物输送相结合,考虑到纳米平台的临床转化。我们选择基于氧化铁的纳米粒子具有立方形状,因为它们在 MH 临床条件下具有出色的发热性能,这使它们成为 MH 的基准试剂。然而,实现像我们的氧化铁纳米立方这样的强相互作用纳米粒子的表面引发聚合仍然是需要克服的主要挑战。在这里,我们证明通过简单地用紫外线 (UV) 光照射铜介导的聚合来加速聚合,可以在每个纳米立方上加速聚合物壳的生长,这既可以加快聚合速度,又可以防止纳米立方聚集。此外,我们在此证明这些 TR-立方可以携带化疗药物阿霉素(DOXO-负载的 TR-立方),而不会影响其在体外和体内的热响应性。体内疗效研究表明,仅在接受 DOXO-负载的 TR-立方治疗并暴露于 MH 时,动物的肿瘤完全抑制和最高存活率。静脉注射的 TR-立方的生物分布在 1 周内显示出肾脏清除的迹象,并且在 5 个月后完全清除。该生物医学平台在临床 MH 条件下运行,并且铁剂量低,这将使双重 MH/热介导化疗的转化成为可能,从而克服 MH 的临床局限性:即能够通过磁共振成像 (MRI) 监测 MH 治疗后的肿瘤进展。